These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
353 related articles for article (PubMed ID: 15251831)
1. Effects of d-chiro-inositol in lean women with the polycystic ovary syndrome. Iuorno MJ; Jakubowicz DJ; Baillargeon JP; Dillon P; Gunn RD; Allan G; Nestler JE Endocr Pract; 2002; 8(6):417-23. PubMed ID: 15251831 [TBL] [Abstract][Full Text] [Related]
2. Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome. Nestler JE; Jakubowicz DJ; Reamer P; Gunn RD; Allan G N Engl J Med; 1999 Apr; 340(17):1314-20. PubMed ID: 10219066 [TBL] [Abstract][Full Text] [Related]
3. Metabolic and hormonal effects of myo-inositol in women with polycystic ovary syndrome: a double-blind trial. Costantino D; Minozzi G; Minozzi E; Guaraldi C Eur Rev Med Pharmacol Sci; 2009; 13(2):105-10. PubMed ID: 19499845 [TBL] [Abstract][Full Text] [Related]
4. Metformin therapy increases insulin-stimulated release of D-chiro-inositol-containing inositolphosphoglycan mediator in women with polycystic ovary syndrome. Baillargeon JP; Iuorno MJ; Jakubowicz DJ; Apridonidze T; He N; Nestler JE J Clin Endocrinol Metab; 2004 Jan; 89(1):242-9. PubMed ID: 14715857 [TBL] [Abstract][Full Text] [Related]
5. Pioglitazone Therapy Increases Insulin-Stimulated Release of d-Chiro-Inositol-Containing Inositolphosphoglycan Mediator in Women with Polycystic Ovary Syndrome. Gupta A; Jakubowicz D; Nestler JE Metab Syndr Relat Disord; 2016 Oct; 14(8):391-396. PubMed ID: 27028341 [TBL] [Abstract][Full Text] [Related]
6. Insulin-stimulated release of D-chiro-inositol-containing inositolphosphoglycan mediator correlates with insulin sensitivity in women with polycystic ovary syndrome. Cheang KI; Baillargeon JP; Essah PA; Ostlund RE; Apridonize T; Islam L; Nestler JE Metabolism; 2008 Oct; 57(10):1390-7. PubMed ID: 18803944 [TBL] [Abstract][Full Text] [Related]
7. Role of inositolphosphoglycan mediators of insulin action in the polycystic ovary syndrome. Nestler JE; Jakubowicz DJ; Iuorno MJ J Pediatr Endocrinol Metab; 2000; 13 Suppl 5():1295-8. PubMed ID: 11117673 [TBL] [Abstract][Full Text] [Related]
8. [Evaluation of the treatment with D-chiro-inositol on levels of oxidative stress in PCOS patients]. De Leo V; La Marca A; Cappelli V; Stendardi A; Focarelli R; Musacchio MC; Piomboni P Minerva Ginecol; 2012 Dec; 64(6):531-8. PubMed ID: 23232537 [TBL] [Abstract][Full Text] [Related]
9. Altered D-chiro-inositol urinary clearance in women with polycystic ovary syndrome. Baillargeon JP; Diamanti-Kandarakis E; Ostlund RE; Apridonidze T; Iuorno MJ; Nestler JE Diabetes Care; 2006 Feb; 29(2):300-5. PubMed ID: 16443877 [TBL] [Abstract][Full Text] [Related]
11. Randomized, double blind placebo-controlled trial: effects of myo-inositol on ovarian function and metabolic factors in women with PCOS. Gerli S; Papaleo E; Ferrari A; Di Renzo GC Eur Rev Med Pharmacol Sci; 2007; 11(5):347-54. PubMed ID: 18074942 [TBL] [Abstract][Full Text] [Related]
12. Treatment with d-chiro-inositol and alpha lipoic acid in the management of polycystic ovary syndrome. Fruzzetti F; Capozzi A; Canu A; Lello S Gynecol Endocrinol; 2019 Jun; 35(6):506-510. PubMed ID: 30612488 [TBL] [Abstract][Full Text] [Related]
13. Evaluation of ovarian function and metabolic factors in women affected by polycystic ovary syndrome after treatment with D-Chiro-Inositol. Laganà AS; Barbaro L; Pizzo A Arch Gynecol Obstet; 2015 May; 291(5):1181-6. PubMed ID: 25416201 [TBL] [Abstract][Full Text] [Related]
14. Comparison between effects of myo-inositol and D-chiro-inositol on ovarian function and metabolic factors in women with PCOS. Pizzo A; Laganà AS; Barbaro L Gynecol Endocrinol; 2014 Mar; 30(3):205-8. PubMed ID: 24351072 [TBL] [Abstract][Full Text] [Related]
15. Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome. Pasquali R; Gambineri A; Biscotti D; Vicennati V; Gagliardi L; Colitta D; Fiorini S; Cognigni GE; Filicori M; Morselli-Labate AM J Clin Endocrinol Metab; 2000 Aug; 85(8):2767-74. PubMed ID: 10946879 [TBL] [Abstract][Full Text] [Related]
16. Potential role and therapeutic interests of myo-inositol in metabolic diseases. Croze ML; Soulage CO Biochimie; 2013 Oct; 95(10):1811-27. PubMed ID: 23764390 [TBL] [Abstract][Full Text] [Related]
17. Decreases in ovarian cytochrome P450c17 alpha activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome. Nestler JE; Jakubowicz DJ N Engl J Med; 1996 Aug; 335(9):617-23. PubMed ID: 8687515 [TBL] [Abstract][Full Text] [Related]
18. Reduction in hematocrit level after pioglitazone treatment is correlated with decreased plasma free testosterone level, not hemodilution, in women with polycystic ovary syndrome. Berria R; Gastaldelli A; Lucidi S; Belfort R; De Filippis E; Easton C; Brytzki R; Cusi K; Jovanovic L; DeFronzo R Clin Pharmacol Ther; 2006 Aug; 80(2):105-14. PubMed ID: 16890572 [TBL] [Abstract][Full Text] [Related]
19. Testosterone is associated with insulin resistance index independently of adiposity in women with polycystic ovary syndrome. Luotola K; Piltonen TT; Puurunen J; Morin-Papunen LC; Tapanainen JS Gynecol Endocrinol; 2018 Jan; 34(1):40-44. PubMed ID: 28678568 [TBL] [Abstract][Full Text] [Related]
20. Lean women with polycystic ovary syndrome respond to insulin reduction with decreases in ovarian P450c17 alpha activity and serum androgens. Nestler JE; Jakubowicz DJ J Clin Endocrinol Metab; 1997 Dec; 82(12):4075-9. PubMed ID: 9398716 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]